IL15 Kite news supporting likely good indication that ZIOP positioned for success
IL15 is a potent longevity factor for T stem cell compartment as well as increasing numbers and activity. This study demonstrating that pre- conditioning chemotherapy caused the production of IL15, expansion of CART and remissions. ZIOP membrane bound IL15 able to be regulated within the CART by velemedex will limit associated toxicity that was observed in the KITE trial and at the same time can regulate up or down the numbers and activity of the CART as required to fight the cancer optimally......all without chemotherapy. KITE gets an initial burst of IL15 activity but cannot keep it going whereas ZIOP could potentially keep IL15 on longer or turn it on again as required. This is important science that ZIOP is controlling.